Commission acts on CHMP Esmya advice
Executive Summary
The European Commission has “opened the way” for Gedeon Richter to relaunch in European markets the Esmya (ulipristal acetate) women’s healthcare brand, after adopting an opinion from the CHMP recommending measures to minimise the risk of rare but serious liver injury.
You may also be interested in...
EMA Safety Panel Recommends Withdrawing Esmya Authorizations
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the European Medicines Agency’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
EMA Safety Commission Recommends Withdrawal Of Esmya Authorizations
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the EMA’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
Stricken Endo Eyes $6bn Debt Cut With Bankruptcy Filing And Restructuring
A group of Endo debtholders are looking to buy the firm out of bankruptcy, with an initial $6bn bid for the stricken firm that envisions setting aside more than half-a-billion dollars for opioid-related claims. Meanwhile, Endo has reached an agreement-in-principle to resolve opioid-related claims.